Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: A report from the children's oncology group

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 6, 2007, Pages 369-375

  Salzer, Wanda L ^a,h   Devidas, Meenakshi ^b,c   Shuster, Jonathan J ^c   Wang, Chenguang ^b,c   Chauvenet, Allen ^d   Asselin, Barbara L ^e   Camitta, Bruce M ^f   Kurtzberg, Joanne ^g  

^a KEESLER MEDICAL CENTER   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d Childrens Oncology Group   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f Midwest Children's Cancer Center   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h Pediatric Hematology/Oncology   (United States)

Author keywords

Antimetabolite; Asparaginase; Childhood acute lymphoblastic leukemia

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; CYTARABINE; DIPHENHYDRAMINE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGY; ARTICLE; B CELL LYMPHOMA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN ATROPHY; BRONCHOSPASM; CANCER SURVIVAL; CANDIDEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GRAM NEGATIVE SEPSIS; HEMORRHAGIC PANCREATITIS; HUMAN; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS DISEASE; PANCREATITIS; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; RESPIRATORY DISTRESS; SEIZURE; SERUM SICKNESS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 34250018555     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3180640d54     Document Type: Article

References (19)

1. SEER Cancer Statistics Review 1975-2003. Five year relative survival rates, National Cancer Institute. Table XXVIII-8.
2. Sallan SE, Gelber RD, Kimball V, et al. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus. 1990;33:459-466.
3. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14:2205-2222.
4. Nachman JB, Sather HN, Sensel MG, et al. Augmented postinduction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
5. Mahoney DH Jr, Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol. 1998;16:246-254.
6. Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43:5601-5607.
7. Maloney KW, Shuster JJ, Murphy S, et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia. 2000;14:2276-2285.
8. Camitta B, Mahoney D, Leventhal B, et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol. 1994;12:1383-1389.
9. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780-1786.
10. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26:217-226.
11. Capizzi RL. Asparaginase revisited. Leuk Lymphoma. 1993;10(suppl):147-150.
12. Asselin B, Kurtzberg J. Asparaginase. In: Pui C-H, ed. Treatment of Acute Leukemias: New Directions for Clinical Research. Totowa, NJ: Humana Press, Inc; 2003:365-380.
13. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24.
14. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218.
15. Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108:2216-2222.
16. Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21:3616-3622.
17. Harris MB, Shuster JJ, Pullen J, et al. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study. Leukemia. 2000;14:1570-1576.
18. Wacker P, Land VJ, Camitta BM, et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. Submitted.
19. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13:335-342.